Results 271 to 280 of about 1,048,882 (334)
UBL3 Participates in the Early Stages of CD83-Dependent CD4<sup>+</sup> T Cell Selection. [PDF]
Morgan H +3 more
europepmc +1 more source
Distinct Immunomodulatory Strategies Guide Mesenchymal Stromal/Stem Cell‐Mediated Bone Regeneration
Bone regeneration by mesenchymal stem cells is strongly influenced by immune signals. This study shows that priming stem cells with regulatory immune cells or an inflammation‐resolving lipid molecule enhances bone formation through distinct immune pathways.
Salwa Suliman +5 more
wiley +1 more source
To address the limitations of protein‐based ICIs in applications, this study constructed an engineered bacterium, HRB, capable of expressing aCD47 in hypoxic TME. Through the Schiff base reaction, responsive liposomes (LC) loaded with the STING agonist cGAMP were connected to the surface of bacteria to form HRB@LC.
Peng‐Shuo Dong +9 more
wiley +1 more source
Pyruvate kinase muscle 2 (PKM2) promotes CD4 T cell survival by regulating pyruvate oxidation during homeostasis and expansion. [PDF]
Subleski JJ +7 more
europepmc +1 more source
A programmable nanoreactor was engineered for precise cGAS‐STING pathway activation in cancer immunotherapy. This strategy bridges targeted tumor DNA damage with DC immunomodulation, providing a translatable platform to unlock innate and adaptive antitumor immunity.
Shuang Liang +14 more
wiley +1 more source
Type 2 inflammation accelerates CD4<sup>+</sup> T-cell senescence in asthma. [PDF]
Liu H, Li Z, Sun Y, Aili A, Chang C.
europepmc +1 more source
A universal ROR1 antibody‐engineered lipid nanoparticle (LNP) is constructed by sequential drug encapsulation and antibody conjugation. The LNP not only enables enhanced chemotherapeutic efficiency by targeting drug delivery and precise localization of deep‐seated tumors through NIR‐II fluorescence imaging, but also remodels immunosuppressive TME ...
Yeneng Dai +12 more
wiley +1 more source
Long pentraxin 3 (PTX3) regulates IL-17A-mediated immunity to <i>Leishmania major</i> infection in mice. [PDF]
Gupta G +6 more
europepmc +1 more source
This study developed a novel drug delivery platform that overcomes the blood‐brain barrier in glioblastoma. By fusing IGFBP7 with small extracellular vesicles, the platform specifically targets tumor vasculature. It effectively delivers temozolomide, suppressing tumor growth at low doses.
Lingling Liu +17 more
wiley +1 more source

